Policosanol to Manage Dyslipidemia in Older Adults

Complementary and Alternative Therapies and the Aging Population

Volumn , Issue , 2009, Pages 117-134

  Swanson, Barbara ^a   Keithley, Joyce ^a  

^a RUSH UNIVERSITY COLLEGE OF NURSING   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84866559593     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-374228-5.00007-X     Document Type: Chapter

References (65)

1. Gouni-Berthold I., Berthold H.K. Policosanol: Clinical pharmacology and therapeutic significance of a new lipid-lowering agent. Am Heart J 2002, 143:356-365.
2. Natural Medicines Comprehensive Database, online version (2007).
3. Uribarri E., Laguna A., Sierra R., Ricardo Y. Physico-mechanical characterization of policosanol, a novel hypocholesterolemic drug. Drug Dev Ind Pharm 2002, 28:89-93.
4. Mas R., Castano G., Illnait J., Fernandez L., Fernandez J., Aleman C., Pontigas V., Lescay M. Effects of policosanol in patients with type II hypercholesterolemia and additional coronary risk factors. Clin Pharmacol Ther 1999, 65:439-447.
5. Castano G., Mas R., Arruzazabala M.L., Noa M., Illnait J., Fernandez J.C., Molina V., Menendez A. Effects of policosanol and pravastatin on lipid profile, platelet aggregation, and endothelemia in older hypercholesterolemic patients. Int J Clin Pharmacol Res 1999, 19:105-116.
6. Castano G., Mas R., Fernandez J.C., Lopez L.E., Fernandez L. A long-term, open-label study of the efficacy and tolerability of policosanol in patients with high global coronary risk. Curr Ther Res 1999, 60:379-391.
7. Castano G., Mas R., Fernandez J.C., Fernandez L., Illnait J., Lopez E. Effects of policosanol on older patients with hypertension and type II hypercholesterolemia. Drugs R D 2002, 3:159-172.
8. Illnait J., Castano G., Mas R., Fernandez J.C. A comparative study on the efficacy and tolerability of policosanol and simvastatin for treating type II hypercholesterolemia [Abstract]. Can J Cardiol 1997, 13(Suppl B):342B.
9. Pons P., Illnait J., Mas R., Rodriquez M., Aleman C., Fernandez J.C., Fernandez L., Martin M. A comparative study of policosanol versus probucol in patients with hypercholesterolemia. Curr Ther Res 1997, 58:26-35.
10. Menendez R., Fernandez S.I., Del Rio A., Gonzalez R.M., Fraga V., Amor A.M., Mas R.M. Policosanol inhibits cholesterol biosynthesis and enhances low density lipoprotein processing in cultured human fibroblasts. Biol Res 1994, 27:199-203.
11. Menendez R., Amor A.M., Rodeiro I., Gonzalez R.M., Gonzalez P.C., Alfonso J.L., Mas R. Policosanol modulates HMG-CoA reductase activity in cultured fibroblasts. Arch Med Res 2001, 32:8-12.
12. Singh D.K., Li L., Porter T.D. Policosanol inhibits cholesterol synthesis in hepatoma cells by activation of AMP-kinase. J Pharmacol Exp Ther 2006, 318:1020-1026.
13. Kabir Y., Kimura S. Biodistribution and metabolism of orally administered octacosanol in rats. Ann Nutr Metab 1993, 37:33-38.
14. Ng C., Leung K.Y., Huang Y., Chen Z.Y. Policosanol has no antioxidant activity in human low-density lipoprotein but increases excretion of bile acids in hamsters. J Agric Food Chem 2005, 53:6289-6298.
15. Menendez R., Mas R., Amor A.M., Gonzalez R.M., Fernandez J.C., Rodeiro I., Zayas M., Jimenez S. Effects of policosanol treatment on the susceptibility of low density lipoprotein (LDL) isolated from healthy volunteers to oxidative modification in vitro. Br J Clin Pharmacol 2000, 50:255-262.
16. Noa M., Mas R., Mesa R. Effect of policosanol on intimal thickening in rabbit cuffed carotid artery. Int J Cardiol 1998, 67:124-132.
17. Noa M., de la Rosa M.C., Mas R. Effect of policosanol on foam-cell formation in carrageenan-induced granulomas in rats. J Pharm Pharmacol 1996, 48:306-309.
18. Kabir Y., Kimura S. Biodistribution and metabolism of orally administered octacosanol in rats. Ann Nutr Metab 1993, 37:33-38.
19. Menendez R., Maarrero D., Mas R., Fernandez I., Gonzalez L., Gonzalez R.M. In vitro and in vivo study of octacosanol metabolism. Arch Med Res 2005, 36:113-119.
20. Janikula M. Policosanol: A new treatment for cardiovascular disease. Altern Med Rev 2002, 7:203-217.
21. Alcocer L., Fernandez L., Campos E., Mas R. A comparative study of policosanol versus acipimox in patients with type II hypercholesterolemia. Int J Tissue React 1999, 21:85-92.
22. Fernandez L., Mas R., Illnait J., Fernandez J.C. Policosanol: Results of a postmarketing surveillance study of 27,879 patients. Curr Ther Res Clin Exp 1998, 59:717-722.
23. Aleman C., Puig M.N., Elias E.C., Ortega C.H., Guerra I.R., Ferreiro R.M., Brinis F. Carcinogenicity of policosanol in mice: An 18-month study. Food Chem Toxicol 1995, 33:573-578.
24. Aleman C.L., Mas R., Hernandez C., Rodeiro I., Cerejido E., Noa M., Capote A., Menendez R., Amor A., Fraga V., Capote A., Jiminez S. A 12-month study of policosanol oral toxicity in Sprague-Dawley rats. Toxicol Lett 1994, 70:77-87.
25. Mesa A.R., Mas R., Noa M., Hernandez C., Rodeiro I., Gamez R., Garcia M., Capote A., Aleman C.L. Toxicity of Policosanol in beagle dogs: One-year study. Toxicol Lett 1994, 73:81-90.
26. Aleman C.L., Mas Ferreiro R., Noa Puig M., Rodeiro Guerra I., Hernandez Ortega C., Capote A. Carcinogenicity of policosanol in Sprague Dawley rats: A 24 month study. Teratog Carcinog Mutagen 1994, 14:239-249.
27. Valdes S., Arruzazabala M.L., Fernandez L., Mas R., Carbajal D., Aleman C., Molina V. Effect of policosanol on platelet aggregation in healthy volunteers. Int J Clin Pharmacol Res 1996, 16:67-72.
28. Rodriguez, M. D. & Garcia, H. (1998). Evaluation of peri- and post-natal toxicity of policosanol in rats. Teratog Carcinog Mutagen,18, 1-7.
29. Batista J., Stusser R., Saez F., Perez B. Effect of policosanol on hyperlipidemia and coronary heart disease in middle-aged patients. A 14-month pilot study. Int J Clin Pharmacol Ther 1996, 34:134-137.
30. Brunton L.L., Lazo J.S., Parker K.L. Goodman & Gilman's the Pharmacological Basis of Therapeutics 2006, McGraw-Hill, New York. 11th ed.
31. Katzung B.G. Basic and Clinical Pharmacology 2004, McGraw-Hill, Stamford, CT. 9th ed.
32. Molina Cuevas V., Arruzazabala M.L., Carbajal Quintana D., Mas Ferreiro R., Valdes Garcia S. Effect of policosanol on arterial blood pressure in rats. Study of the pharmacological interaction with nifedipine and propranolol. Arch Med Res 1998, 29:21-24.
33. Chen J.T., Wesley R., Shamburek R.D., Pucino F., Csako G. Meta-analysis of natural therapies for hyperlipidemia: Plant sterols and stanols versus policosanol. Pharmacotherapy 2005, 25:171-183.
34. Lin, Y., Rudrum, M., van der Wielen, R. P. J., Trautwein, E. A., McNeill, G., Sierksma, A. & Meijer, G. W. (2004). Wheat germ policosanol failed to lower plasma cholesterol in subjects with normal to mildly elevated cholesterol concentrations. Metabolism53, 1309-1314.
35. Castano G., Fernandez L., Mas R., Illnait J., Gamez R., Mendoza S., Mesa M., Fernandez J. Effects of addition of policosanol to omega-3 fatty acid therapy on the lipid profile of patients with type II hypercholesterolaemia. Drugs R D 2005, 6:207-219.
36. Castano G., Mas R., Fernandez L., Illnait J., Mendoza S., Gamez R., Fernandez J., Mesa M. A comparison of the effects of D-003 and policosanol (5 and 10mg/day) in patients with type II hypercholesterolemia: A randomized, double-blinded study. Drugs Exp Clin Res 2005, 31(Suppl):31-44.
37. Reiner Z., Tedeschi-Reiner E., Romic Z. Effects of rice policosanol on serum lipoproteins, homocysteine, fibrinogen, and C-reactive protein in hypercholesterolemic patients. Clin Drug Invest 2005, 25:701-707.
38. Wright C.M., Zielke J.C., Whayne T.F. Policosanol, an aliphatic alcohol sugarcane derivative: Use in patients intolerant of or inadequately responsive to statin therapy. Int J Angiology 2005, 13:173-175.
39. Berthold H.K., Unverdorben S., Degenhardt R., Bulitta M., Gouni-Berthold I. Effect of policosanol on lipid levels among patients with hypercholesterolemia or combined hyperlipidemia: A randomized controlled trial. JAMA 2006, 295:2262-2269.
40. Castano G., Arruzazabala M.L., Fernandez L., Mas R., Carbajal D., Molina V., Illnait J., Mendoza S., Gamez R., Mesa M., Fernandez J. Effects of combination treatment with policosanol and omega-3 fatty acids on platelet aggregation: A randomized, double-blind clinical trial. Curr Ther Res 2006, 67:174-192.
41. Cubeddu L.X., Cubeddu R.J., Heimowitz T., Restrepo B., Lamas G.A., Weinberg G.B. Comparative lipid-lowering effects of policosanol and atorvastatin: A randomized, parallel, double-blind, placebo-controlled trial. Am Heart J 2006, 152:e1-e5.
42. Dulin M.F., Hatcher L.F., Sasser H.C., Barringer T.A. Policosanol is ineffective in the treatment of hypercholesterolemia: A randomized controlled trial. Am J Clin Nutr 2006, 84:1543-1548.
43. Greyling A., DeWitt C., Oosthuizen W., Jerling J.C. Effects of a policosanol supplement on serum lipid concentrations in hypercholesterolaemic and heterozygous familial hypercholesterolaemic subjects. Br J Nutr 2006, 95:968-975.
44. Kassis A.M., Jones P.J.H. Lack of cholesterol-lowering efficacy of Cuban sugar cane policosanols in hypercholesterolemic persons. Am J Clin Nutr 2006, 84:1003-1008.
45. Cicero A.F.G., Rovati L.C., Setnikar I. Eulipidemic effects of berberine administered alone or in combination with other natural cholesterol-lowering agents: A single-blind clinical investigation. Arzneimittel-Forschung 2007, 57:26-30.
46. Murota K., Kawada T., Matsui N., Sakakibara M., Takahashi N., Fushiki T. Oleyl alcohol inhibits intestinal long-chain fatty acid absorption in rats. J Nutr Sci Vitaminol 2000, 2000:302-308.
47. Castano G., Canetti M., Moreira M., Tula L., Mas R., Illnait J., Fernandez L., Fernandez J.C., Diaz E. Efficacy and tolerability of policosanol in elderly patients with type II hypercholesterolemia: A 12-month study. Curr Ther Res 1995, 56:819-828.
48. Ortensi G., Julio G., Hector V., Pedro A.T. A comparative study of policosanol versus simvastatin in elderly patients with hypercholesterolemia. Curr Ther Res 1997, 58:390-401.
49. Castano G., Mas R., Arruzazabala M.L., Noa M., Illnait J., Fernandez J.C., Molina V., Menendez A. Effects of policosanol and pravastatin on lipid profile, platelet aggregation and endothelemia in older hypercholesterolemic patients. Int J Clin Pharmacol Res 1999, 19:105-116.
50. Castano G., Mas R., Fernandez J.C., Illnait J., Fernandez L., Alvarez E. Effects of policosanol in older patients with type II hypercholesterolemia and high coronary risk. J Gerontol A Biol Sci Med Sci 2001, 56:M186-M192.
51. Mas R., Castano G., Fernandez L., Illnait J., Fernandez J., Alvarez E. Effects of policosanol on lipid profile and cardiac events in older hypercholesterolemic patients with coronary disease. Clin Drug Invest 2001, 21:485-497.
52. Castano G., Mas R., Fernandez J.C., Fernandez L., Illnait J., Lopez E. Effects of policosanol on older patients with hypertension and type II hypercholesterolemia. Drugs R D 2002, 3:159-172.
53. Castano G., Mas R., Fernandez L., Illnait J., Mesa M., Alvarez E., Lezcay M. Comparison of the efficacy and tolerability of policosanol with atorvastatin in elderly patients with type II hypercholesterolemia. Drugs Aging 2003, 20:153-163.
54. Castano G., Mas R., Gamez R., Fernandez J., Illnait J., Fernandez L., Mendoza S., Mesa M., Gutierrez J.A., Lopez E. Concomitant use of policosanol and beta-blockers in older patients. Int J Clin Pharmacol Res 2004, 24:65-77.
55. Fernandez S., Mas R., Gamez R., Arquimedes D., Fernandez J., Orta S.D., Illnait J., Castano G., Mendoza S., Valdes F., Alvarez E. A pharmacological surveillance study of the tolerability of policosanol in the elderly population. Am J Geriatr Pharmacother 2004, 2:219-229.
56. United States House of Representatives Committee on Government Reform (2005). New Medicare drug plans fail to provide meaningful drug discount prices.
57. Bellosta S., Paoletti R., Corsini A. Safety of statins: Focus on clinical pharmacokinetics and drug interactions. Circulation 2004, 109(Suppl III):III-50-III-57.
58. Weiss J., Dormann S.M.G., Martin-Facklam M., Kerpen C.J., Ketabi-Kiyanvash N., Haefeli W.E. Inhibition of P-glycoprotein by newer antidepressants. J Pharmacol Exp Ther 2003, 305:197-204.
59. Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation 2004, 109(Suppl III):III-39-III-43.
60. Vaughn C.J. Prevention of stroke and dementia with statins: Effects beyond lipid lowering. Am J Cardiol 2003, 91:23B-29B.
61. Jick H., Zornberg G.L., Jick S.S., Seshadri S., Drachman D.A. Statins and the risk of dementia. Lancet 2000, 356:1627-1631.
62. Young-Xu Y., Chan K.A., Liao J.K., Ravid S., Blatt C.M. Long-term statin use and psychological well-being. J Am Coll Cardiol 2003, 42:690-697.
63. Alsheikh-Ali A.A., Maddukuri P.V., Han H., Karas R.H. Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer: Insights from large randomized statin trials. J Am Coll Cardiol 2007, 50:409-418.
64. Dale K.M., Coleman C.I., Henyan N.N., Kluger J., White C.M. Statins and cancer risk: A meta-analysis. JAMA 2006, 295:74-80.
65. Poynter J.N., Gruber S.B., Higgins P.D., Almog R., Bonner J.D., Rennert H.S., Low M., Greenson J.K., Rennert G. Statins and the risk of colorectal cancer. N Engl J Med 2005, 352:2184-2192.